Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
Blood Advances|July 21, 2026
Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxisJoseph A Pidala, Jongphil Kim, Jose Laborde, et al.Transplantation and Cellular Therapy|July 21, 2022
Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic MalignancyCatherine J Lee, Tao Wang, Karen Chen, et al.Transplantation and Cellular Therapy|June 20, 2021
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD ReportZachariah DeFilipp, Daniel R Couriel, Aleksandr Lazaryan, et al.Transplantation and Cellular Therapy|December 30, 2022
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical TrialBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2021
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2017
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell TransplantationRobert J Soiffer, Haesook T Kim, Joseph McGuirk, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 16, 2014
Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromesChristine N Duncan, Navneet S Majhail, Ruta Brazauskas, et al.Blood|June 20, 2026
Expanded antigen-specific donor regulatory T cells for GVHD preventionJoseph A Pidala, Nicoletta Cieri, Michael J Schell, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 4, 2019
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell TransplantationBetty K Hamilton, Ying Liu, Michael T Hemmer, et al.Blood Advances|May 10, 2018
Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplantsAnita J Kumar, Soyoung Kim, Michael T Hemmer, et al.Pageof 5